Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Emgality ® (galkanezumab)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as "2019 novel coronavirus."1
Eli Lilly and Company has not studied the use of galcanezumab in patients with COVID-19.
CGRP mAbs Have no Direct Specific Immunomodulatory Effect
The CGRP mAbs have been engineered to bind to either the CGRP peptide or receptor with high specificity and minimized interaction with the immune system.2-4
Antibodies, also referred to as immunoglobulins, are composed of 2 identical heavy and 2 identical light chains.3 These chains contain variable and constant sections, involved in antigen binding and biological activity, respectively. Five isotypes exist in humans including IgA, IgD, IgE, IgG, and IgM. Therapeutic mAbs are composed of IgG isotypes which are divided into 4 subclasses in order of decreasing serum concentrations including IgG1 to IgG4.4
Therapeutic mAbs are introduced into the host for a specific purpose.3
Galcanezumab is a humanized IgG4 mAb that
binds CGRP, thus
preventing its biological activity.5
Infectious Disease Resources
For the most current information regarding the coronavirus, please refer to the WHO website:
1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed March 11, 2020.
2. Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics. 2018;15(2):324-335. http://dx.doi.org/10.1007/s13311-018-0622-7
3. Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55(8):1171-1182. http://dx.doi.org/10.1111/head.12642
4. Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache. 2018;58(10):1689-1696. http://dx.doi.org/10.1111/head.13439
CGRP = calcitonin gene-related peptide
Ig = immunoglobulin
IgA = immunoglobulin A
IgD = immunoglobulin D
IgE = immunoglobulin E
IgG = immunoglobulin G
IgG4 = immunoglobulin G (subclass) 4
IgM = immunoglobulin M
mAb = monoclonal antibody
WHO = World Health Organization
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2020 M03 11